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Growing teratoma syndrome is rare and usually it occurs in the younger aged group. The use of chemotherapy following initial
surgical resection will yield the diagnosis following tumour enlargement. Complete resection is usually curative and renders better
prognosis.
1.Introduction
This report concerned a young patient with growing ter-
atoma syndrome who required complete resection. Resid-
ual disease is the commonest suspicion following fertility
conserving surgery for immature teratoma of ovary in a
young woman. Administration of adjuvant chemotherapy
is the usual course pathway for management of residual
disease. An enlarging intraperitoneal mass despite course of
chemotherapy is usually due to treatment failure but rarely
may be as a result of growing teratoma syndrome. Complete
resection is essential to prevent progression of tumour and
is often curative, hence, it will render better prognosis as
mature teratoma, are resistant to both chemotherapy and
radiotherapy.
2. Case Presentation
A 17-year-old, nonparous girl presented with a one-month
history of noticeable pelvic mass and was diagnosed to have
a left ovarian tumour in 2007 with a raised serum CA-125
of 350IU/L. Other tumour markers were not performed
due to ﬁnancial constraint. An intraoperative frozen section
revealed immature teratoma and she underwent fertility
sparing surgery. A staging laparotomy with left salpingo-
oophorectomy, peritoneal cytology, pelvic lymph nodes
sampling, and infracolic omentectomy was performed. Post-
operative histology report revealed mature teratoma with
focal area of immature teratoma of the left ovary. There
was no malignant cell inﬁltration to the omentum or lymph
nodes. Histology revealed immature teratoma grade I, FIGO
stage 1a. Despite being advised for close surveillance, she
defaulted followup after 6 months postoperative.
One year later, she presented with lower abdominal
discomfort and resought medical advice. She developed
radiological recurrence of pelvic mass with a raised serum
CA-125of180IU/Lfollowingwhichshecompleted6courses
of systemic chemotherapy (carboplatin-paclitaxel). After
chemotherapy, the tumour marker normalised (<35IU/L)
but the pelvic mass progressively increased in size. CT
scan of the abdomen and pelvis revealed presence of
bilateral large adnexal masses with inﬁltration into uterus
and also possibly to the sigmoid colon. Growing teratoma
syndrome was suspected. She underwent staging laparotomy
and complete excision of the tumour. Full bilateral pelvic
lymphadenectomy was done. Postoperative CT scan of the
abdomen and pelvis showed no residual disease. Histology
of excised mass revealed mature teratoma with no presence2 Case Reports in Obstetrics and Gynecology
of immature cells. The patient remained with no recurrence
at the time of this report, which is 8 months after the second
operation for GTS.
3. Discussion
Female ovarian growing teratoma syndrome (GTS), a rare
encounter, is deﬁned as an enlarging mature teratoma that
arises during or following chemotherapy for a malignant
germ cell tumor [1]. Five years later, it was renamed as
“chemotherapeutic retroconversion.” The pathogenesis of
this rare occurrence remained debatable. Selective elimina-
tion of the malignant cells by chemotherapeutic agents or
diﬀerentiation of malignant cells into mature teratoma com-
ponents following exposure to chemotherapeutic agents may
bethetwopossiblemechanismsresponsiblefordevelopment
of GTS. As a result, often this is misinterpreted as chemo-
resistanttumourorrecurrence.Completeresectionisthekey
to a longer remission, however, the dilemma arises usually in
younger women. Very few cases are reported on young Asian
women with management still being debatable [2–7].
The youngest age reported in the literature is 5 years old
[3]. The initial presenting symptoms are usually abdomi-
nal distension or discomfort. The initial histopathology is
usually immature teratoma. As GTS mainly occurs in the
young patient or with fertility concern, the initial surgery
they usually underwent unilateral salpingo-oophorectomy.
It is noted that the decision for lymphadenectomy is done
not in all patient but it has been reported to have better
local control and lowered the disease progression to GTS.
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months and in some cases, delayed till 8 years. Monitoring
of response to chemotherapy is by serum tumour markers
till low or normal levels [2–18]. This is one of the ﬁrst
reported growing teratoma from a completely excised stage
1a immature teratomas. The possible explanation for the
appearanceof growing teratoma syndrome may be as a result
ofmicrometastasesoftheremainingimmatureteratomacells
within the peritoneal cavity. This may be as a result of intra-
abdominal dissemination despite intact capsule which may
occur spontaneously preoperatively.
Despite normalization of serum tumour markers during
chemotherapy, the metastatic tumour grows and is usually
identiﬁed on radiological imaging or ultrasonography. The
feature usually reported in literature is soft pelvic tissue
mass on CT scan or echogenic mass on ultrasound pelvis.
Complete surgical excision is the treatment of choice with
retroperitonealpelvicandpara-aorticlymphnodedissection
[2–12, 14–17, 19]. Most patient had laparotomy excision of
tumour mass rather than by laparoscopy. This is probably
due to adequacy concern of the selected method. Patients
who had complete excision had longer disease-free interval
up to 8 years with lowered recurrence episodes [6]. GTS
varied in growth rate and is chemoresistant in most cases
[2, 3, 11–13]. Early decision for complete resection had
lowered morbidity in this patient as with delay, GTS that
can grow rapidly may encase the blood vessels and other
vital structures leading to pressure eﬀect and potential
risk of vascular thrombosis, ureteral obstruction, bowel
obstruction, or colonic ﬁstula [1–9, 12, 16–19]. The majority
of mortality of GTS is related to postoperative complications
[18]. Malignant transformation has been reported up to 3%
of cases [16, 17]. The predetermining factors for develop-
ment of GTS were reported as incomplete resection of
primary tumour, presence of mature teratoma cells in the
initial histology and no reduction in the size of tumour after
chemotherapy [12].
GTS has an overall good prognosis with only a few
reported deaths [4, 5, 18, 19]. The 5-year overall survival
rate of patients who had underwent surgery following GTS
is 89% [18]. However, close regular followup is essential as
recurrence may ensue up to the 10 years after the initial
diagnosis [6, 12]. GTS had been reported to have even
occurred following a successful pregnancy [6].
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